Phase Ib/II Clinical Study of QLS5133 Combination Therapy in Advanced Solid Tumors
Key facts
- Who runs it
- Qilu Pharmaceutical Co., Ltd.
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 1/2
- People taking part
- 558 people, planned
- Started
- 15 Nov 2026
- Expected to end
- 15 Nov 2029
- Type of study
- Interventional, 6 groups
- Treatments tested
- QLS5133; Lenvatinib mesylate
- QLS5133; QL2107; Lenvatinib mesylate
- QLS5133; Bevacizumab
- QLS5133; Platinum; Bevacizumab
- QLS5133; Olaparib; Bevacizumab
- QLS5133; QL2107; Bevacizumab
- Record updated
- 12 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (16)Hide the full registry criteria
Who can take part
- 1. Histologically or cytologically confirmed advanced solid tumors, with specific tumor type and prior treatment requirements per each cohort
- 2. Measurable disease per RECIST v1.1 (except Cohorts 3B-1, 3B-2, and 5B)
- 3.Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- 4.Adequate organ function
- 5.Recover from all reversible AEs from previous anti-tumor treatment (i.e., Grade ≤ 1, according to NCI-CTCAE v6.0), excluding alopecia (any grade) and Grade ≤ 2 neuropathy peripheral
Who cannot take part
- 1.Prior treatment with CDH6-targeted agents or topoisomerase I inhibitors (including ADCs)
- 2.Prior treatment with immune checkpoint inhibitors (for Cohorts 2 and 6 only)
- 3.Prior Grade 4 or persistent ≥ 4-week Grade 3 immune-related AEs from immune checkpoint inhibitors
- 4.Prior systemic anti-tumor therapy (for Cohorts 1B-2 and 2B-2 only)
- 5.Recent anti-tumor therapy within specified washout periods (small molecules: 2 weeks; biologics/chemotherapy: 4 weeks; mitomycin/nitrosoureas: 6 weeks)
- 7. Serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection
- 8.History of significant cardiac disease, or poorly controlled diabetes mellitus
- 9.History of recurrent autoimmune diseases
- 10. History of a second primary malignancy
- 11.Be allergic to any component of QLS5133 or its excipients
- 6.Active or symptomatic CNS metastases or leptomeningeal carcinomatosis
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Clear cell renal cell carcinoma or ovarian cancer
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), and effectiveness of the investigational drug QLS5133 (injectable) in combination with other therapies for participants with advanced solid tumors. This is a multicenter, open-label study consisting of two parts: dose escalation and tumor-specific expansion.
Read full original descriptionShow less
The main questions it aims to answer are:
* In the dose-escalation part: What is the safety, tolerability, PK profile, and preliminary efficacy of QLS5133 combination therapy, and what are the recommended dose(s) for expansion? * In the expansion part: What is the anti-tumor efficacy and further safety profile of QLS5133 combination therapy at the selected dose(s) in participants with specific tumor types?
Participants will:
* Be enrolled in sequential cohorts to receive QLS5133 in combination with other anticancer agents. * Undergo regular assessments for safety, drug concentration levels (PK), and tumor response.
The 6 groups in the trial
- Arm 1Treatment being tested
QLS5133 in combination with lenvatinib mesylate
Treatment: QLS5133; Lenvatinib mesylate
- Arm 2Treatment being tested
QLS5133 in combination with lenvatinib mesylate plus QL2107
Treatment: QLS5133; QL2107; Lenvatinib mesylate
- Arm 3Treatment being tested
QLS5133 in combination with bevacizumab
Treatment: QLS5133; Bevacizumab
- Arm 4Treatment being tested
QLS5133 in combination with platinum-based therapy with or without bevacizumab, followed by QLS5133 alone or in combination with bevacizumab
Treatment: QLS5133; Platinum; Bevacizumab
- Arm 5Treatment being tested
QLS5133 in combination with olaparib with or without bevacizumab
Treatment: QLS5133; Olaparib; Bevacizumab
- Arm 6Treatment being tested
QLS5133 in combination with QL2107 with or without bevacizumab
Treatment: QLS5133; QL2107; Bevacizumab
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase Ib/II Clinical Study on the Safety, Tolerability, Pharmacokinetics, and Efficacy of Intravenous QLS5133 Combination Therapy in Participants With Advanced Solid Tumors
- Criteria questions
- Built from NCT07933419, who can take part
- Record updated
- 12 November 2026